NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Affect Therapeutics

Affect Therapeutics

Private
McLean, VirginiaHealthcare & Life Scienceshttps://www.affect.com/

Last Round

Series B

Nov 5, 2025

Total Funding Raised

$75.3M

Company Overview

Affect Therapeutics is a digital health company that provides a smartphone-based virtual clinic for substance use and mental health disorders, utilizing contingency management, counseling, and medication-assisted treatment.

Sector

Healthcare & Life Sciences

Verticals

Mental Health, Telemedicine, Patient Engagement

Business Model

B2B2C

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

substance use disordercontingency managementdigital healthDTxaddiction recoverydigital therapeuticsstimulant addictionbehavioral healthtelehealthvirtual clinicclinical decision supportCDSgamified therapyrecovery appvalue-based care

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Affect Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Affect Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Affect Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BNov 5, 2025
Series BSep 23, 2025
Series AJul 12, 2023
GrantSep 30, 2021
SeedAug 31, 2021
Seed
Apr 21, 2021

Key People

Founding team and executive leadership

Russell Osborne

Chief Technology Officer

Executive Team

Scott Joseph Fries

Chief Financial Officer

Executive Team

Bryan Prout

Chief Operating Officer

Executive Team

Affect Therapeutics Investors

Notable investors and investment history

Affect Therapeutics investors
InvestorRounds
AlleyCorpSeed, Series A
ARTIS VenturesSeries B, Series A
Samsung Next TLVSeries A
LifeArc VenturesSeries B, Series A
Kapor CapitalSeed
AcumenSeed
What If VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 16, 2024

    Grew 16% QoQ, from 91 to 106 employees.

  • Mar 22, 2024

    Grew 19% QoQ, from 83 to 99 employees.

Affect Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Affect Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Affect Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersMcLean, Virginia
Employee Range153
Year Founded2020
Last FundingNov 5, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.